HBHoward C. Becker

Howard C. Becker

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Howard C. Becker has a total of 170 co-authors. Here are the top co-authors by number of shared publications:

  • Marcelo F. Lopez

    Department of Psychiatry and Behavioral Sciences Medical University of South Carolina Charleston South Carolina USA

    14 shared publications
  • William C. Griffin

    Charleston Alcohol Research Center, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina

    10 shared publications
  • Marcelo Lopez

    Department of Psychiatry and Behavioral Sciences, Addiction Sciences Division, Medical University of South Carolina, Charleston, SC, 29425, USA

    7 shared publications
  • Courtney E. King

    Charleston Alcohol Research Center, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina

    6 shared publications
  • Rachel Ivy Anderson

    Department of Psychiatry and Behavioral Sciences Medical University of South Carolina Charleston SC USA

    6 shared publications
  • Harold L. Haun

    Charleston Alcohol Research Center, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina

    5 shared publications

Latest Publications

  • A Scoping Review of Preclinical Paradigms for Clinically Tested Medications in Alcohol Use Disorder

    by Steven J. Nieto, Suzanna Donato, Wave‐Ananda Baskerville, Kaitlin R. McManus, Marcelo F. Lopez, Howard C. Becker, Lara A. Ray

    Despite increasing attention to the neurobiology of alcohol use disorder (AUD), development of effective pharmacotherapies remains limited. Many medications with promising preclinical profiles fail to translate into clinical efficacy. This scoping review characterizes preclinical studies evaluating medications for AUD that have also been tested in human laboratory paradigms or clinical trials. We focus on two widely used paradigms: the two‐bottle choice (2 BC ) task, which measures alcohol consumption and preference, and operant reinstatement models, which capture relapse‐like behavior. A systematic search and data extraction identified preclinical studies using 2 BC and reinstatement paradigms to evaluate medications that progressed to human testing. Study characteristics (species, strain, sex, outcomes, and sample sizes) were recorded and effect sizes (corrected Cohen's d ) were summarized across outcome domains. Ninety‐two unique studies met criteria: 74 employing the 2 BC paradigm and 18 using operant reinstatement models, including 1731 animals. Rats were the most common species and sex bias was pronounced: 77 2 BC studies using only males, five only females, and all 18 reinstatement studies used male rats exclusively. For 2 BC consumption, the largest effects were observed for medications with limited studies, such as levetiracetam ( d = −4.58), while more extensively tested medications showed moderate effects, including prazosin ( d = −0.74) and naltrexone ( d = −0.63). For 2 BC preference, levetiracetam again showed a large effect in a single study ( d = −4.29). In reinstatement models, rimonabant showed the largest effect ( d = −3.11), while naltrexone ( d = −0.70), baclofen ( d = −1.05), and varenicline ( d = −0.72) had moderate effects. This review highlights substantial heterogeneity in study design and underutilization of reinstatement and female animals. Medications with moderate, replicable preclinical effects, especially those tested across both 2 BC and reinstatement models, may hold greater translational promise. These findings offer key opportunities for enhancing the translational alignment of preclinical AUD pharmacotherapy research.

  • Open Access

    Engaging Gut‐to‐Brain Signalling to Treat Alcohol Use Disorder

    by Paula L. Hoffman, Giordano de Guglielmo, Valentina Vengeliene, Wolfgang Kunze, Christina L. Lebonville, Jerome D. Swinny, Amanda J. Roberts, Olivier George, Karen‐Anne McVey Neufeld, Alexandra Dunbar, et al.

    According to the 2023 National Survey on Drug Use and Health (NSDUH), 28.9 million people ages 12 and older in the United States had alcohol use disorder (AUD) in the past year. Although chronic alcohol use contributes to numerous health disorders as well as being an economic burden, there are few medications approved for treatment of AUD, and these medications are not uniformly effective and are not widely used. We now describe studies of a small molecule, novel chemical entity called Nezavist, which shows promise as a medication to treat AUD and possibly other addictive disorders. Nezavist acts as a positive allosteric modulator at a novel site on the GABA A receptor, but pharmacokinetic analysis demonstrates that Nezavist does not enter the CNS. However, Nezavist effectively reduces relapse to chronic alcohol consumption in alcohol‐dependent animals in two widely used models. An important goal of the current studies is to provide evidence for the hypothesis that Nezavist acts in the intestine to stimulate vagus nerve afferents that project to the brainstem (nucleus tractus solitarius), leading to reduced inflammation in the brain that may alleviate alcohol ‘craving’ during abstinence from alcohol. It is hoped that the presentation of the current results will stimulate interest in further confirmation of the mechanism of action of Nezavist, with the intent of developing a new and effective medication for treatment for AUD.


  • Open Access

    G9a inhibition reduces stress‐potentiated alcohol drinking in both male and female mice: Implications for safe and effective pharmacological therapeutics for alcohol use disorder

    by Deltrice Holmes, Marcelo F. Lopez, Howard C. Becker, Christopher W. Cowan, Ethan M. Anderson

    Background: Alcohol use disorder (AUD) is a chronic, relapsing disease that is difficult to treat, and current therapies are not effective for many patients. Clinical studies show that stress increases heavy alcohol consumption and that stress is a predominant factor in rates of relapse. As such, pharmacotherapies that reduce stress‐related alcohol drinking might be beneficial clinically. We recently showed that viral vector‐mediated reduction of the epigenetic enzyme G9a (also known as euchromatic histone‐lysine N‐methyltransferase 2 or EHMT2) in the nucleus accumbens blocks stress‐potentiated alcohol drinking. In addition, repeated systemic administration of the G9a inhibitor UNC0642 also reduces stress‐potentiated alcohol drinking, suggesting that G9a inhibitors might be effective for treating AUD. Methods: Here, we further investigated the potential for UNC0642 to be used clinically to treat AUD. We first tested the effective dose of UNC0642 in multiple models of alcohol consumption in both male and female mice. We also tested half‐life, oral bioavailability, maximum tolerated dose, and many measures of behavioral toxicity. Results: We found that UNC0642 is effective at reducing stress‐potentiated alcohol consumption in both male and female mice at lower doses than we previously reported, and we re‐confirmed the anxiolytic‐like effects of UNC0642. We also found that UNC0642 has a long half‐life in vivo, is orally bioavailable, is within an acceptable toxicity range for therapeutic use, and does not produce behavioral inhibition in many standard preclinical assessments, including locomotor activity, open field, Y‐maze, rotarod, fear conditioning, sucrose self‐administration, or sucrose‐seeking. Conclusions: Together, our studies suggest that G9a inhibitors could be effective, safe, and novel AUD therapeutics that reduce stress and dependence‐related high levels of alcohol drinking in AUD patients.

  • Open Access

    Exercise (Wheel-Running) Reduces Chronic Alcohol-Induced Escalation of Drinking in Mice via Elevated BDNF-TrkB Receptor Activity

    by Howard Becker, Matthew Solomon, Anny Gano, Marcelo Lopez

    Alcohol use disorder (AUD) is a significant medical problem and there is great need for developing effective treatment strategies. Brain-Derived Neurotrophic Factor (BDNF) has been shown to play a role in regulating numerous pharmacological and motivational effects of alcohol. We have shown that chronic alcohol-induced escalation of drinking is accompanied by a deficit in BDNF levels in medial prefrontal cortex (mPFC). This study examined whether exercise (wheel-running) attenuates excessive alcohol drinking via increased BDNF expression, thereby mitigating the deficit in mPFC. Adult male C57BL/6J mice were given scheduled (2-hr/day) access to a running wheel in the home-cage 1-hr following opportunity to drink alcohol for 2-hr/day. After six weeks, mice were further separated into groups that received chronic alcohol vapor or control (air) inhalation exposure. Results indicated that alcohol consumption did not alter wheel-running and exercise did not alter alcohol intake during the 6-week baseline. Exercise increased BDNF mRNA and protein expression in mPFC, reversed chronic alcohol-induced reduction in BDNF levels, and attenuated escalated alcohol drinking. Systemic administration of a TrkB receptor antagonist (ANA-12) reversed the beneficial effects of wheel-running in the model. Together, these data provide support for exercise as a potentially effective intervention strategy for treating AUD.


  • Open Access

    Cyp2e1 deletion in mice increases sensitivity to ethanol‐induced motor impairment and escalation of drinking behavior in the chronic intermittent ethanol model

    by Hyland C. Gonzalez, Kelly R. Misare, Kate E. Glorioso, Joe R. Delaney, Howard C. Becker, Marcelo F. Lopez, Patrick J. Mulholland, Jessica H. Hartman

    Background: Chronic ethanol use drives numerous neurological dysfunctions. Ethanol in the brain is mainly metabolized into acetaldehyde by catalase and cytochrome P450 2E1 (Cyp2e1), and acetaldehyde does not freely cross the blood–brain barrier. While Cyp2e1 is a well‐known enzyme in liver toxicology, how central nervous system (CNS)‐expressed Cyp2e1 contributes to ethanol toxicity is unknown. Methods: We investigated the effects of Cyp2e1‐driven ethanol metabolism in the brain of male and female global Cyp2e1 knockout (KO) and wild‐type (WT) 129S1/SvImJ mice. RNA‐seq was completed on the medial prefrontal cortex (mPFC), the dorsal and ventral hippocampus, and cerebellum to see whether there are baseline differences in gene expression between WT and KO mice. To investigate acute functional tolerance (AFT), we evaluated blood ethanol concentrations (BECs) of mice on a fixed‐speed rotarod after two consecutive ethanol doses. Next, we used the chronic intermittent ethanol (CIE) exposure model to study dependence‐induced escalation of drinking. After the study, catalase protein expression was analyzed in the mPFC, hippocampus, and cerebellum. Results: Transcriptomic pathway analysis in ethanol‐naïve mice revealed differences in ethanol‐important pathways in both male and female Cyp2e1‐KO mice. Glyoxylase‐1 ( Glo1 ) was downregulated in KO animals. Both WT and Cyp2e1‐KO mice had a similar AFT. However, after both injections, Cyp2e1‐KO mice had to reach a lower BEC to balance on the rotarod ( p < 0.001), indicating increased sensitivity to ethanol intoxication. In the drinking study, Cyp2e1‐KO mice drank more than WT controls during baseline drinking sessions ( p < 0.01, n = 8–9). After CIE exposure, only Cyp2e1‐KO mice significantly escalated their drinking ( p < 0.001, n = 16–17). Catalase levels were not significantly higher in KO mice in the brain regions studied regardless of condition. Conclusions: This study reveals an important role for Cyp2e1 in ethanol‐related behaviors and highlights a need to better understand the effects of ethanol and its metabolites in mediating ethanol drinking and sensitivity.


  • Open Access

    Exercise (Wheel-Running) Reduces Chronic Alcohol-Induced Escalation of Drinking in Mice via Elevated BDNF-TrkB Receptor Activity

    by Howard C Becker, Matthew G Solomon, Anny Gano, Marcelo F Lopez

    Alcohol use disorder (AUD) is a significant medical problem and there is great need for developing effective treatment strategies. Brain-Derived Neurotrophic Factor (BDNF) has been shown to play a role in regulating numerous pharmacological and motivational effects of alcohol. We have shown that chronic alcohol-induced escalation of drinking is accompanied by a deficit in BDNF levels in medial prefrontal cortex (mPFC). This study examined whether exercise (wheel-running) attenuates excessive alcohol drinking via increased BDNF expression, thereby mitigating the deficit in mPFC. Adult male C57BL/6J mice were given scheduled (2-hr/day) access to a running wheel in the home-cage 1-hr following opportunity to drink alcohol for 2-hr/day. After six weeks, mice were further separated into groups that received chronic alcohol vapor or control (air) inhalation exposure. Results indicated that alcohol consumption did not alter wheel-running and exercise did not alter alcohol intake during the 6-week baseline. Exercise increased BDNF mRNA and protein expression in mPFC, reversed chronic alcohol-induced reduction in BDNF levels, and attenuated escalated alcohol drinking. Systemic administration of a TrkB receptor antagonist (ANA-12) reversed the beneficial effects of wheel-running in the model. Together, these data provide support for exercise as a potentially effective intervention strategy for treating AUD.

  • Open Access

    Targeting G9a decreases escalated alcohol drinking in male mice in a model of combined stress and chronic alcohol exposure

    by Marcelo F. Lopez, Paulina Misztak, Howard C. Becker, Christopher W. Cowan, Ethan M. Anderson

    Background: Alcohol use disorder (AUD) is a pervasive problem in society afflicting millions of people worldwide. One reason for the prevalence of AUD is that heavy alcohol drinking can produce alcohol dependence. In addition, alcohol dependence dysregulates the body's stress systems to increase alcohol drinking. Therefore, targeting dependence‐ and/or stress‐related alcohol drinking clinically could reduce heavy drinking in patients with AUD. One key mechanism thought to contribute to behaviors associated with AUD is long‐lasting epigenetic alterations of gene expression. We recently showed that the epigenetic regulatory enzyme G9a (also known as euchromatic histone‐lysine N‐methyltransferase 2 or EHMT2) is downregulated in the nucleus accumbens (NAc) in mice by alcohol dependence produced by the chronic intermittent alcohol (CIE) model. Also, we showed that either viral‐mediated NAc G9a knockdown or a systemically administered G9a inhibitor reduced stress‐potentiated alcohol drinking by the kappa‐opioid agonist U50,488.Methods: Here, we tested whether NAc G9a knockdown reduces escalated alcohol drinking in a mouse model of combined dependence plus forced swim stress (CIE + FSS) in male mice. We also tested for changes in sucrose drinking, sucrose preference, and water consumption as controls. In addition, we tested whether systemic administration of a G9a inhibitor, UNC0642, could reduce alcohol drinking in the CIE + FSS model.Results: We found that either NAc G9a knockdown or repeated systemic UNC0642 administration reduced escalated ethanol drinking following CIE + FSS, but without altering control levels of ethanol drinking or sucrose drinking or water drinking in male mice.Conclusions: These preclinical data suggest that reducing NAc G9a levels, or suppressing its enzymatic activity, can effectively reduce potentiated alcohol drinking produced by stress and/or alcohol dependence. These data suggest that G9a inhibition holds promise as a potential therapeutic for individuals who suffer from AUD.


  • Open Access

    Translating medication effects for alcohol use disorder across preclinical, human laboratory, and clinical trial outcomes using meta-analysis

    by Steven J. Nieto, Suzanna Donato, Han Du, Lindsay R. Meredith, Wave-Ananda Baskerville, Kaitlin R. McManus, Molly Magill, Marcelo F. Lopez, Howard C. Becker, Lara A. Ray

    Animal models are used for preliminary testing of novel compounds for alcohol use disorder (AUD). However, it is unclear whether early efficacy in preclinical models reliably predicts efficacy in human laboratory and clinical trials. We searched the literature for medications tested for AUD in preclinical models (i.e., two-bottle choice [2-BC] and operant reinstatement), human laboratory cue-reactivity, and randomized clinical trials (RCTs). For preclinical models, we computed medication effects on 2-BC alcohol preference and consumption (k = 77 studies, 14 medications) as well as operant reinstatement (k = 18 studies, 8 medications). For human laboratory studies, we computed medication effects on alcohol cue-induced craving (k = 36 studies, 15 medications). For RCTs, we computed medication effects on RCT endpoints including return to any drinking and return to heavy drinking (k = 139 studies, 19 medications). We used medication as the unit of analysis and applied the Williamson-York bivariate weighted least squares estimation to preserve the errors in both the independent and dependent variables. Medication effects on 2-BC alcohol preference ( $$\hat{\beta }$$ β ˆ = 0.04, p = 0.004) and reinstatement ( $$\hat{\beta }$$ β ˆ = 0.20, p = 0.05) were positively associated with medication effects on return to any drinking in human clinical trials but no associations were found on other RCT outcomes tested. Preclinical medications findings were not associated with medication effects on cue-induced craving in the human laboratory. Medication findings on 2-BC alcohol preference and operant reinstatement track medication effects on select clinical trial outcomes, specifically return to any drinking. This study provides empirical support for the association between medication effects across species and experimental models, a critical, yet untested, premise of preclinical studies in medications development.


  • Open Access

    Alcohol drinking is associated with greater calcium activity in mouse central amygdala dynorphin-expressing neurons

    by Christina L. Lebonville, Jennifer A. Rinker, Krysten O'HAra, Christopher S. McMahan, Michaela Hoffman, Howard C. Becker, Patrick J. Mulholland


  • Open Access

    Increased alcohol‐biased choice behavior in mouse models of high alcohol drinking

    by Marcelo F. Lopez, Howard C. Becker

    Background: Rodent models have explored the transition from controlled goal‐directed consumption to habitual/compulsive intake using different procedures. This study evaluates the effect of concurrent presentation of sucrose on alcohol intake using two models that induce high levels of alcohol intake in mice that experienced chronic intermittent ethanol (CIE) exposure and/or stress.Methods: In Experiment 1, male mice were exposed to four cycles of CIE or control (air) exposure, and once an increase in voluntary alcohol was observed in CIE mice, mice were offered a choice between alcohol or increasing concentrations of sucrose (from 0.75% to 12%; w/v). In Experiment 2, male mice experienced three cycles of CIE exposure, CIE and forced swim stress, control (air) exposure, or forced swim stress. Once elevated voluntary alcohol intake was observed in mice that experienced both CIE and stress, mice were presented with a choice between alcohol and sucrose (from 1.5% to 6%, w/v increased over consecutive days).Results: Mice that experienced CIE exposure (Experiment 1) or CIE exposure and stress (Experiment 2) showed increased alcohol intake. In Experiment 1, the presentation of sucrose at 3% and 12% reduced alcohol intake in control mice. Only the two highest concentrations of sucrose (6% and 12%) affected alcohol intake in CIE‐exposed mice. In Experiment 2, concurrent presentation of a 6% sucrose solution decreased alcohol intake in mice that experienced CIE, stress, or control exposure; however, the presentation of sucrose did not influence alcohol intake in mice that experienced both CIE and stress. The amount of sucrose consumed did not differ between groups in both experiments.Conclusions: These experiments showed that mice that had experienced repeated CIE exposure alone or in combination with stress were more prone to continue their high levels of alcohol intake despite the presence of a sucrose solution as an alternative.